Form 4: Cartesian Therapeutics CFO Sells Shares for Tax

Cartesian Therapeutics CFO Blaine Davis sold 10,591 shares of common stock to cover tax obligations and broker fees related to restricted stock unit vesting.

Summary

• Blaine Davis, Chief Financial Officer of Cartesian Therapeutics, Inc. (RNAC), reported a sale of common stock.
• The transaction involved the disposition of 10,591 shares of Common Stock.
• The shares were sold at a price of $6.8197 per share.
• The sale was conducted on January 6, 2026.
• Following this transaction, Blaine Davis beneficially owns 121,220 shares of Common Stock.
• The purpose of the sale was to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (sale for tax obligations) which is generally considered neutral. It does not indicate a change in company fundamentals or management's confidence.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Comparison to Industry Standards

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary sale for tax purposes, not a signal of management's view on future performance.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the Chief Financial Officer to cover tax obligations and broker fees associated with the vesting of restricted stock units. Such transactions are common for executives receiving equity compensation and do not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, based solely on this filing, there is no new information to warrant a change from a 'hold' position, assuming the investor's prior assessment of the company's fundamentals remains unchanged.

Keywords

Cartesian Therapeutics, RNAC, Blaine Davis, CFO, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Obligations, Biotechnology, Pharmaceuticals